Microsens' vCJD (variant Creutzfeldt-Jakob disease) trials may start in 12 months:
This article was originally published in Clinica
Microsens Biotechnologies has told Clinica that it expects to begin human trials of its human variant Creutzfeldt-Jakob disease (vCJD) blood test within the next 12 months. The test uses a ligand-based technology called Seprion to identify abnormal prion proteins in the blood (see Clinica No 1125, p 21). The firm's comment follows this month's EU approval of Idexx Laboratories' BSE test, HerdChek, which uses Microsens' Seprion technology. Microsens CEO, Christopher Stanley, said that Idexx' EU approval represented "another stake in the ground towards providing a vCJD blood test." The London, UK-based company said it would need 20-30 positive vCJD blood samples to begin the trials.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.